PM received honoraria from Bristol Myers Squibb/Celgene, Janssen-Cilag, AbbVie, Amgen, Takeda, Oncopeptides, Sanofi, and GlaxoSmithKline. AC served as a consultant or in an advisory role for Amgen, Janssen Oncology, Seattle Genetics, Karyopharm Therapeutics, Genzyme, Oncopeptides, Takeda, Antengene, GlaxoSmithKline, Secura Bio, Shattuck Labs, Genentech, AbbVie, and Bristol Myers Squibb/Celgene; and received research funding from Celgene, Janssen, Amgen, Seattle Genetics, Takeda, and Pharmacyclics. AO served on advisory boards for Sanofi, GlaxoSmithKline, Bristol Myers Squibb, Amgen, and Janssen. JM-L consulted for, received honoraria from, and served on a board of directors or advisory committees for Janssen; consulted for and received research funding from Bristol Myers Squibb and Incyte; and consulted for Novartis. MH received honoraria from Amgen, Novartis, Roche, Celgene, Takeda, and Bayer. CT received honoraria from and served in a consulting or advisory role for Janssen, Celgene, Takeda, Amgen, and AbbVie; and had travel, accommodations, or other expenses paid or reimbursed by Janssen, Takeda, Amgen, and AbbVie. SA served as a consultant for GlaxoSmithKline, Sanofi, Bristol Myers Squibb, Takeda, BeiGene, Pharmacyclics, Amgen, and Janssen; and received research funding from GlaxoSmithKline, Bristol Myers Squibb, Pharmacyclics, Amgen, Janssen, Cellectar, Xencor, and AbbVie. BB received honoraria from Janssen, Amgen, Takeda, and Sanofi. JdlRC received honoraria from Bristol Myers Squibb/Celgene, Jansen-Cilag, Amgen, Takeda, Sanofi, and GlaxoSmithKline; and received travel support from Janssen-Cilag. CE received honoraria from Bristol Myers Squibb/Celgene, Janssen-Cilag, Amgen, Sanofi, and GlaxoSmithKline. M-VM received honoraria derived from lectures and participation in advisory boards from Janssen, Celgene, Takeda, Amgen, GlaxoSmithKline, AbbVie, Pfizer, Regeneron, Adaptive Biotechnologies, Roche, and Seattle Genentech. HS received honoraria from Bristol Myers Squibb/Celgene, Janssen-Cilag, AbbVie, Amgen, Takeda, Oncopeptides, Sanofi, and GlaxoSmithKline; and received travel support from Bristol Myers Squibb/Celgene, Janssen-Cilag, AbbVie, Amgen, Sanofi, and GlaxoSmithKline. PR-O participated in speakers bureaus for and received honoraria from Bristol Myers Squibb/Celgene, Janssen, Amgen, GlaxoSmithKline, Sanofi, Regeneron, and Oncopeptides. CH received honoraria from Janssen, Bristol Myers Squibb, Amgen, Takeda, and AbbVie. LK served on advisory boards for and/or received honoraria or travel support from Celgene/Bristol Myers Squibb, Janssen, Takeda, Amgen, and GlaxoSmithKline. ASB served as a consultant for, received honoraria from, and participated in speakers bureaus for Takeda. LR received honoraria from Janssen, Celgene, Amgen, Takeda, Sanofi, and GlaxoSmithKline. HT served on an advisory board for Bristol Myers Squibb; and participated in speakers bureaus for ADP. SY, JW, IN, MQ, and MK are employees of Janssen Research & Development, LLC, and may hold equity. MD was employed by Janssen Research & Development, LLC, at the time of the study. HG received grants and/or provision of Investigational Medicinal Products from Amgen, Bristol Myers Squibb, Celgene, Chugai, Dietmar Hopp Foundation, Janssen, Johns Hopkins University, and Sanofi; received research support from Amgen, Bristol Myers Squibb, Celgene, Chugai, Janssen, Incyte, Molecular Partners, Merck Sharp & Dohme, Sanofi, Mundipharma GmbH, Takeda, and Novartis; served on advisory boards for Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Celgene, Janssen, Sanofi, and Takeda; and received honoraria from Amgen, Bristol Myers Squibb, Celgene, Chugai, GlaxoSmithKline, Janssen, Novartis, and Sanofi. JB, LB, and ST have nothing to disclose.